The Inside Track: LogiPharma was a Microcosm of Pharma Supply Chains’ Present and Future

Returning from this year's LogiPharma conference in Vienna, I had intended to use the flight home to rest. Instead, the conversations of the previous three days kept surfacing, and by the time we crossed the Alps, I had my laptop open.

Little of what I heard in Vienna was new. As someone who covers EMEA, I've been having variations of these conversations with leaders across the life sciences industry for months: temperature excursions identified too late, dashboards that fall short of delivering actionable insight, and a quiet consensus that no one is planning for a stable year ahead.

What made LogiPharma worth attending was the way it consolidated those signals. Concerns I had been hearing in isolation across the region were, for three days, voiced collectively and with notably greater urgency.

Clearly, pharmaceutical supply chains are now carrying demands they were not designed to meet, and the leaders accountable for them have largely stopped suggesting otherwise. Yet the industry continues to articulate a vision of the future that present capabilities cannot yet support.

That disconnect, between aspiration and operational reality, is what I want to focus on  here, rather than the conference itself.

Initial Impressions From the LogiPharma Floor

LogiPharma pulled the full cast into Vienna for three days: service providers, packaging companies, specialty logistics firms, Pharmaceutical and Biotech manufacturers, medtech companies, and more—all on the same floor. The exhibitor list told one story. The badges walking the aisles told a sharper one.

Product owners and shippers turned up in real numbers this year, and they came with specific questions. Service levels. Product integrity. Sustainability. How to keep operating when disruption stops being the exception.

Five years ago, most of that would have gone to a 3PL and stayed there, but pharma supply chains have stopped delegating that work. The pharma and medtech teams who visited the Tive booth weren't browsing: they wanted direct oversight over their shipments, and they wanted to know who could give it to them.

True Visibility is About Integrity, Not Only Location

That demand sharpens once you look at what's moving through these lanes.

Pharma and medtech share a baseline most industries would envy, where on-time arrival is the floor rather than the goal. The harder question is whether the shipment turned up in the same condition it was in when it left the warehouse, and nobody has fully solved that yet.

An ultrasound system, for instance, can take a hard knock somewhere over the Atlantic and roll off the truck looking perfectly fine… and nobody knows otherwise until a tech tries to calibrate it the following week and the readings drift. By then, a patient gets rescheduled, and a service team ends up explaining itself to hospital procurement.

It plays out the same way at the smaller end. A customer of ours in Switzerland ships $10,000 spare parts for eye surgery lasers, and every hour that part is in transit is an hour a surgeon somewhere has a procedure on hold. A delivery confirmation doesn't tell that team what they need to know. They need to know they can install the part the day it lands, which means knowing what it went through to get there.

The Risks Aren't Hidden Anymore

You can't talk about condition without talking about the route, and the route is where things sometimes get strange.

Every session I sat through in Vienna eventually came back to the same short list: conflict zones, closed or constrained routes, rising fuel costs, cargo theft that's gotten more sophisticated over the last two years, and delays across key trade lanes.

None of that is news. What is news, though, is the tone. People stopped describing it as a rough patch or something temporary. It feels more like the new normal now.

I don't worry so much about lanes inside Europe or inside the U.S. Those are usually fine. The ones I lose sleep over run the other direction. APIs and raw materials come out of India and China, change hands four or five times, and have to land in a plant in Ireland or New Jersey on a date someone committed to a year ago. When one leg of that goes sour, you don't lose a shipment. You lose an entire quarter.

Every shipper I work with has accepted that something on the route will eventually go wrong, and most of them are still writing the same incident report twice a year about it. That's the working reality for pharma supply chains now.

After the Fact is Too Late

Planning for exceptions also only works if you find out about them in time to do something.

For a long time, that meant trusting a logistics provider to flag the problems, and trusting a temperature datalogger to fill in the rest. The logger came off the truck at the destination, somebody plugged it into a laptop, and a week later, you had your temperature curve. 

That's if the logger came back. And if anyone read the file. And (more and more often these days) if the receiving site's IT team hadn't disabled USB ports on the laptops for security reasons.

Pharma supply chains have outgrown the model where you and the customer find out about an excursion at the same time, and real-time tracking will eventually take its place.

Pharma Cannot Afford After-the-Fact Visibility

A delay you can't do anything about is just a story for the postmortem.

I had some version of this conversation a dozen times in Vienna, and I have it on customer calls regularly. Pharma and medtech can't simply book a late shipment as a P&L hit and move on. If a clinical trial delivery misses its window, a patient misses a treatment. If a cell or gene therapy gets mishandled, you're starting the manufacturing run over, if you even can.

Knowing afterward doesn't help any of those people. Shippers want real-time shipment visibility that lets them pick up the phone while a shipment is still moving, not after it's parked. That's where pharma supply chains are putting their money.

Pharma's AI Problem Isn't the AI Itself

AI came up in almost every session in Vienna, and it comes up in almost every customer call I'm on.

Most of the talk is what you'd expect. How do we use it, where does it fit, and what can it predict? What I keep noticing is the hesitation underneath some of it. A few pharma companies and quality leads told me, more or less, that the part they're stuck on is what they'll be obligated to do once a model surfaces something they can't ignore.

That's a fair thing to be stuck on. Pharma supply chains run on documentation cycles, governance reviews, and CAPA processes that take months to move. A risk flagged on a normal weekday doesn't help much when your organization needs a quarter to respond to it.

Most of the people I work with already know this. They're moving on AI at the pace their organization can absorb, which is slower than the demos and yet faster than doing nothing.

Why Tive Keeps Coming Up

That pace problem is part of why I left Vienna feeling good about where Tive sits in this market.

I'll keep this short because the alternative will sound like I'm pitching. The Tive booth was full for three days, meetings ran long, and conversations with 3PLs, packaging partners, and pharma medtech prospects had real substance. The kind where people open up about what's actually broken inside their operation.

That doesn't happen unless they've already decided you're worth their time. A few things, I think, are behind it:

• Real volume, not slide volume: Tive moves millions of devices a year, and more than 130,000 every month. When a Pharma company asks whether we've handled their type of lane, the answer is usually that we already are.
• A customer list that spans the entire LogiPharma exhibit floor: Global 3PLs, specialty logistics providers, packaging companies, pharma manufacturers, life sciences, medtech. Working across all of them gives us a view of the full handoff chain, which is exactly where most pharma supply chains break down.
• Showing up where it counts: Our leadership was on the exhibit floor in Vienna, spoke in sessions, and attended many of the meetings. Strategic prospects notice when the people making the decisions are the ones doing the talking.
• Momentum in a crowded room: Pharma and life sciences visibility has no shortage of providers, but some of them have left the race to compete in Life Science and Pharma. Tive has gone in the other direction, and the companies deciding who to work with next year have clocked the difference.
• Concept vs. traction: What I felt at LogiPharma was the market starting to sort vendors with a pitch from partners with a track record. That sort of thing is happening now, and it's the conversation Tive wants to be part of.

My Honest Take

The customers I sit with don't want another dashboard or another logger that they have to chase down at the destination. They want to open an app first thing in the morning, see that a pallet bound for Frankfurt is running two hours behind and trending warm, and call the carrier before it becomes a quality event. That's the day-to-day reality Tive is built for, across pharma supply chains where the cost of finding out late shows up in patients, not just paperwork.

LogiPharma reminded me how many teams are still working without that. If yours is one of them, get started with Tive today.